NC-2800
Depression
Phase 2aActive - Patient enrollment started as of Jan 2026
Key Facts
Indication
Depression
Phase
Phase 2a
Status
Active - Patient enrollment started as of Jan 2026
Company
About Nippon Chemiphar
Japanese pharmaceutical company developing generics, allergy treatments, and novel drugs including a δ-opioid receptor agonist for depression.
View full company profileTherapeutic Areas
Other Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| Depression Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| Depression Study | Sun Valley Research Center | Not Disclosed |
| eTNS Platform | NeuroSigma | Unknown |
| ALM003 | Almatica Pharma | Phase 3 |
| ALM014 | Almatica Pharma | Pivotal BA/BE |
| NRCT-101SR | Neurocentria | Phase 2b/3 |
| Starstim for Depression | Neuroelectrics | Phase 1/2 |
| Depression Biomarkers | Paradise Genomics | Discovery |
| Home-tDCS Depression Trial | Soterix Medical | N/A (Device-enabled trial) |
| BPL-003 | AtaiBeckley | Phase 2 |
| VLS-01 | AtaiBeckley | Phase 2 |